FINWIRES · TerminalLIVE
FINWIRES

BMO表示,在3月份加拿大工资意外增长后,将密切关注加拿大工资走势。

-- 蒙特利尔银行(BMO)表示,加拿大3月份的劳动力调查(LFS)显示,工资同比增长4.7%,创下自2024年10月以来的最高增速,这一数字令人意外。 该银行指出,自那时以来的大约一年半时间里,就业市场显著放松,首先是由于过去的货币紧缩政策,然后是由于与美国的贸易战带来的经济逆风——所有这些都发生在移民政策发生重大转变的背景下。 BMO表示,在这样的背景下,单月工资增长加速0.7个百分点确实引人注目。 加拿大统计局解释说,这是由于职业构成和工作年限的变化而产生的统计异常。换句话说:工资加速增长是因为更多的人从事了更高薪的工作,或者工作时间更长,因此获得了更高的收入。考虑到这些因素,年增长率为3.6%,与过去四个月相比变化不大。 该银行表示,这与一些宏观趋势相符:近期净移民外流对低收入工作的劳动者——换句话说,就是临时外籍劳工和学生——的影响尤为严重。 BMO指出,加之人口老龄化,这也可能导致员工群体向那些工作年限较长的人群倾斜。 该银行补充道,尽管如此,这种转变在上个月突然发生仍然令人惊讶。BMO表示将密切关注这一趋势是否会持续。目前看来,实际工资增长似乎比公布的增长率要低。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF